NZ600118A - Lipopeptide compositions and related methods - Google Patents

Lipopeptide compositions and related methods

Info

Publication number
NZ600118A
NZ600118A NZ600118A NZ60011810A NZ600118A NZ 600118 A NZ600118 A NZ 600118A NZ 600118 A NZ600118 A NZ 600118A NZ 60011810 A NZ60011810 A NZ 60011810A NZ 600118 A NZ600118 A NZ 600118A
Authority
NZ
New Zealand
Prior art keywords
daptomycin
solid pharmaceutical
related methods
composition
lipopeptide compositions
Prior art date
Application number
NZ600118A
Other languages
English (en)
Inventor
Sophie Sun
Sandra O’Connor
Gaauri Naik
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ600118(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of NZ600118A publication Critical patent/NZ600118A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ600118A 2009-11-23 2010-11-23 Lipopeptide compositions and related methods NZ600118A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23
PCT/US2010/057910 WO2011063419A2 (en) 2009-11-23 2010-11-23 Lipopeptide compositions and related methods

Publications (1)

Publication Number Publication Date
NZ600118A true NZ600118A (en) 2014-08-29

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600118A NZ600118A (en) 2009-11-23 2010-11-23 Lipopeptide compositions and related methods

Country Status (33)

Country Link
US (3) US8835382B2 (cg-RX-API-DMAC7.html)
EP (2) EP2504353B2 (cg-RX-API-DMAC7.html)
JP (3) JP6041673B2 (cg-RX-API-DMAC7.html)
CN (3) CN102712677B (cg-RX-API-DMAC7.html)
AR (2) AR079127A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010321531C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012012406B1 (cg-RX-API-DMAC7.html)
CA (1) CA2781666C (cg-RX-API-DMAC7.html)
CL (2) CL2012001336A1 (cg-RX-API-DMAC7.html)
CO (1) CO6541585A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120271A (cg-RX-API-DMAC7.html)
CY (1) CY1120854T1 (cg-RX-API-DMAC7.html)
DK (1) DK2504353T4 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000140A (cg-RX-API-DMAC7.html)
EC (1) ECSP12011939A (cg-RX-API-DMAC7.html)
ES (1) ES2686331T5 (cg-RX-API-DMAC7.html)
FI (1) FI2504353T4 (cg-RX-API-DMAC7.html)
HR (1) HRP20181380T4 (cg-RX-API-DMAC7.html)
HU (1) HUE039967T2 (cg-RX-API-DMAC7.html)
IL (1) IL219891B (cg-RX-API-DMAC7.html)
LT (1) LT2504353T (cg-RX-API-DMAC7.html)
MX (1) MX2012005993A (cg-RX-API-DMAC7.html)
NZ (1) NZ600118A (cg-RX-API-DMAC7.html)
PE (2) PE20121517A1 (cg-RX-API-DMAC7.html)
PL (1) PL2504353T5 (cg-RX-API-DMAC7.html)
PT (1) PT2504353T (cg-RX-API-DMAC7.html)
RS (1) RS57566B2 (cg-RX-API-DMAC7.html)
RU (1) RU2607526C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201407724YA (cg-RX-API-DMAC7.html)
SI (1) SI2504353T2 (cg-RX-API-DMAC7.html)
TR (1) TR201812823T4 (cg-RX-API-DMAC7.html)
TW (2) TWI606838B (cg-RX-API-DMAC7.html)
WO (1) WO2011063419A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
CA2823628A1 (en) 2011-01-05 2012-07-12 Hospira, Inc. Spray drying vancomycin
MX2013013760A (es) * 2011-05-26 2014-01-08 Cubist Pharm Inc Composiciones de cb-183, 315 y metodos relacionados.
US20130184225A1 (en) * 2012-01-12 2013-07-18 Lianfeng Huang Romidepsin formulations and uses thereof
WO2014045296A2 (en) * 2012-08-23 2014-03-27 Agila Specialties Private Limited Improved daptomycin injectable formulation
EP4066849B1 (en) 2012-09-11 2025-03-05 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
ES2946600T3 (es) 2016-10-21 2023-07-21 Xellia Pharmaceuticals Aps Formulaciones líquidas de daptomicina
AU2018322769B2 (en) * 2017-08-31 2021-12-02 Xellia Pharmaceuticals Aps Daptomycin formulations
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
CN114828873A (zh) * 2019-12-26 2022-07-29 尼普洛株式会社 含有达托霉素的稳定的冷冻干燥制剂
JP2023516957A (ja) 2020-02-28 2023-04-21 クセリア ファーマシューティカルズ エーピーエス ダプトマイシン製剤
JP2023517926A (ja) 2020-03-12 2023-04-27 バクスター・インターナショナル・インコーポレイテッド ソルビトールとマンニトールの組み合わせを含むダプトマイシン製剤
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
NZ213731A (en) 1984-10-09 1988-04-29 Lilly Co Eli A-21978c derivatives
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
NZ232763A (en) * 1989-03-06 1991-09-25 Lilly Co Eli Parenteral formulation comprising daptomycin with a buffer to maintain ph between 6.0 and 8.0
ATE160357T1 (de) 1990-01-26 1997-12-15 Hoechst Ag Neues antibiotikum, deoxymulündocandin, verfahren zu seiner produktion und verwendung als medikament
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (cg-RX-API-DMAC7.html) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
FI944900L (fi) 1992-04-20 1994-10-19 Abbott Lab Vankomysiinin valmistusprosessi
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
WO1999027957A1 (en) 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
WO2000018419A2 (en) 1998-09-25 2000-04-06 Cubist Pharmaceuticals, Inc. Methods for administration of antibiotics
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
AU784812B2 (en) 1999-12-15 2006-06-29 Merck Sharp & Dohme Corp. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
NZ523276A (en) * 2000-06-21 2005-02-25 Cubist Pharm Inc Compositions and methods to improve the oral absorption of antimicrobial agents
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20030045678A1 (en) * 2000-12-18 2003-03-06 Dennis Keith Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
US20050027113A1 (en) 2001-08-06 2005-02-03 Miao Vivian Pak Woon Compositions and methods relating to the daptomycin biosynthetic gene cluster
ES2263962T3 (es) 2002-01-17 2006-12-16 Arkema France Polimeros supramoleculares.
WO2004004658A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
CN101080221A (zh) * 2005-02-14 2007-11-28 维纳斯药业有限公司 抗药性细菌感染疾病的肠胃外综合治疗
CA2610716A1 (en) 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
AU2006339311A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0715113A2 (pt) 2006-07-26 2013-06-04 Sandoz Ag Sandoz Sa Sandoz Ltd formulaÇço de caspofungina
WO2008127291A2 (en) 2006-10-10 2008-10-23 Los Alamos National Security, Llc Advanced drug development and manufacturing
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
AU2008269140A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
EP2207584A2 (en) * 2007-10-25 2010-07-21 Novartis Ag Powder conditioning of unit dose drug packages
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
US8901072B2 (en) 2009-08-12 2014-12-02 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
EP2504020A4 (en) 2009-11-23 2013-05-29 Eagle Pharmaceuticals Inc Daptomycin FORMULATIONS
NZ609964A (en) 2010-11-01 2015-08-28 Melinta Therapeutics Inc Pharmaceutical compositions
EP2655314B1 (en) 2010-12-23 2018-02-07 Alkermes Pharma Ireland Limited Multi-api loading prodrugs
EP2670418A4 (en) 2011-02-04 2015-06-17 Aegis Therapeutics Llc ORAL BIO-AVAILABLE PEPTIDARY MATERIAL COMPOSITIONS AND METHOD THEREFOR

Also Published As

Publication number Publication date
CN102712677B (zh) 2015-06-03
TR201812823T4 (tr) 2019-02-21
EP2504353A4 (en) 2014-04-02
JP2017075186A (ja) 2017-04-20
WO2011063419A2 (en) 2011-05-26
CN104056250A (zh) 2014-09-24
CA2781666C (en) 2017-02-21
BR112012012406A2 (pt) 2019-12-03
RS57566B1 (sr) 2018-10-31
HRP20181380T1 (hr) 2018-10-19
ECSP12011939A (es) 2012-07-31
JP6041673B2 (ja) 2016-12-14
TW201703791A (zh) 2017-02-01
JP2016147874A (ja) 2016-08-18
AU2010321531A1 (en) 2012-06-14
CN108785654A (zh) 2018-11-13
JP2013511557A (ja) 2013-04-04
CL2015002412A1 (es) 2016-02-05
IL219891B (en) 2018-01-31
HUE039967T2 (hu) 2019-02-28
HRP20181380T4 (hr) 2023-11-10
MX2012005993A (es) 2012-11-23
CN102712677A (zh) 2012-10-03
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
US9662397B2 (en) 2017-05-30
FI2504353T4 (fi) 2023-11-30
SI2504353T2 (sl) 2023-11-30
LT2504353T (lt) 2018-09-25
PE20151717A1 (es) 2015-11-19
CY1120854T1 (el) 2019-12-11
JP6088681B2 (ja) 2017-03-01
PE20121517A1 (es) 2012-11-26
EP2504353A2 (en) 2012-10-03
AU2010321531B2 (en) 2016-11-03
AR079127A1 (es) 2011-12-28
SI2504353T1 (sl) 2018-10-30
CR20120271A (es) 2012-08-01
IL219891A0 (en) 2012-07-31
US9138456B2 (en) 2015-09-22
US20120270772A1 (en) 2012-10-25
CO6541585A2 (es) 2012-10-16
AU2010321531A2 (en) 2014-10-30
US8835382B2 (en) 2014-09-16
PL2504353T5 (pl) 2023-11-20
ES2686331T5 (es) 2024-03-27
PT2504353T (pt) 2018-10-18
AR123846A2 (es) 2023-01-18
EP2504353B1 (en) 2018-07-11
SG10201407724YA (en) 2014-12-30
EP3417849A1 (en) 2018-12-26
RS57566B2 (sr) 2023-12-29
AU2010321531C1 (en) 2020-10-01
EP2504353B2 (en) 2023-09-13
RU2607526C2 (ru) 2017-01-10
RU2012126076A (ru) 2013-12-27
BR112012012406B1 (pt) 2021-11-16
US20160030577A1 (en) 2016-02-04
DK2504353T4 (da) 2023-11-20
CA2781666A1 (en) 2011-05-26
US20140364380A1 (en) 2014-12-11
ES2686331T3 (es) 2018-10-17
TWI548414B (zh) 2016-09-11
DOP2012000140A (es) 2012-10-30
WO2011063419A3 (en) 2011-10-13
PL2504353T3 (pl) 2018-11-30
CL2012001336A1 (es) 2012-10-05
JP6239167B2 (ja) 2017-11-29
DK2504353T3 (en) 2018-09-10

Similar Documents

Publication Publication Date Title
NZ600118A (en) Lipopeptide compositions and related methods
WO2011072218A3 (en) Stable formulations for lyophilizing therapeutic particles
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
NZ621174A (en) Powdered protein compositions and methods of making same
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
WO2010100200A3 (en) Lyophilised antibody formulation
MY197773A (en) Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody
WO2009007328A3 (de) Verwendung von homo- und copolymeren zur stabilisierung von wirkstoffformulierungen
WO2012076670A3 (en) Antibody formulation
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
PH12012502159A1 (en) Pharmaceutical compositions and methods of making same
MX348823B (es) Formulaciones estables de linaclotida.
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
HK1213174A1 (zh) 穩定的含水依那西普製劑
EP1750862A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
PH12016501877A1 (en) Lypophilized factor ix formulations
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
MY159317A (en) Treating idiopathic thrombocytopenic purpura with compositions comprising extracts of astragalus membranaceus
WO2008079963A3 (en) Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients
GR20130200219U (el) Στερεα φαρμακευτικα σκευασματα λεβοκαρνιτινης σε αναβραζουσα μορφη
HK1234139A1 (en) Lyophilized factor ix formulations

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 NOV 2017 BY COMPUTER PACKAGES INC

Effective date: 20150131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2018 BY THOMSON REUTERS

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2019 BY THOMSON REUTERS

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2020 BY THOMSON REUTERS

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2022 BY THOMSON REUTERS

Effective date: 20211002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2023 BY THOMSON REUTERS

Effective date: 20221003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2024 BY THOMSON REUTERS

Effective date: 20231002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2025 BY THOMSON REUTERS

Effective date: 20241002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2026 BY THOMSON REUTERS

Effective date: 20251001